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16-Slice CT angiography (CTA) in patients with suspected blunt
carotid and vertebral artery injuries
Utter GH, Hollingworth W, Hallam DK, et al. J Am Coll Surg 2006;203:
838-8.
Conclusion: Multidetector computed tomography angiography
(CTA) should supplant digital subtraction angiography (DSA) as a screening
modality for patients with possible carotid or vertebral artery injuries after
blunt trauma.
Summary: Detection of carotid injury after blunt trauma is problem-
atic. With the advent of multidetector CTA and the liberal use of CT
scanning in patients with blunt trauma, CTAmay serve as a viable alternative
to angiography for screening for carotid or vertebral artery injuries after
blunt trauma. In this study, the authors sought to determine whether CTA
performed with a 16-slice multidetector CT scanner can be used as an initial
imagining examination in patients with suspected vertebral artery or carotid
blunt injury. Predictive values of clinical variables for screening for carotid or
vertebral artery injury were also estimated.
This was a retrospective study of patients imaged at a Level 1 trauma
center for suspected blunt carotid or vertebral artery injury in 2004. Patients
were evaluated by CTA if they met criteria suggestive of possible blunt
carotid or vertebral artery injury. These criteria included symptoms or signs
of carotid or vertebral artery injury and various injury mechanisms or
patterns of injury thought to be associated with an increased risk for carotid
or vertebral artery injury. Evaluation included a CTA, and then, at the
discretion of the clinical service, DSA was performed to confirm a negative
CTA. The primary variable evaluated was the proportion of patients with
normal CTAs who also had a normal DSA.
There were 372 patients imaged with CTA for suspect carotid or
vertebral artery injury. Of these, 271 had normal study results, and 82 (30%)
also underwent DSA. DSA was equivocal or normal in 75 of these 82
patients, a 92% negative-predictive value of CTA for carotid or vertebral
artery injury (95% confidence interval [CI], 83% to 97%). The positive-
predictive value for the clinical screening criteria for carotid or vertebral
artery injury was 19% (95% CI, 14% to 23%). Of potential variables predict-
ing carotid or vertebral artery injuries, lateral element cervical vertebral
fractures and skull-based fractures were most predictive of a carotid or
vertebral artery injury.
Comment: Catheter-based angiography should not be routinely re-
quired to rule out carotid or vertebral artery injury in 2007. Unfortunately,
this study has significant limitations that do not permit such a definitive
conclusion. These limitations include the fact not all patients with a negative
CTA had DSA; therefore, the negative-predictive value of CTA may either
be under-estimated or over-estimated by the study. It is also not possible to
determine either the sensitivity or specificity of CTA in detecting carotid or
vertebral artery injury. There was no systematic follow-up of patients to
assess for late stroke, the end point that really matters. Finally, many trauma
centers are now equipped with even more advanced CT scanners, making
the results of this study perhaps obsolete even before publication.
Carotid intimal-media thickening indicates a higher vascular risk across
a wide age range: prospective data from the Carotid Atherosclerosis
Progression Study (CAPS)
Lorenz NW, Von Kegler S, Steinmetz H, et al. Stroke 2006;37:87-92.
Conclusion: Carotid intimal medial thickness (IMT) is a good predic-
tor of vascular events in young people as well as in older patients.
Summary: It is known that in individuals aged 45 years or older,
carotid IMT predicts vascular events. The predictive value of IMT in
younger patients, however, is less appreciated. The authors report results of
the Carotid Atherosclerosis Progression Study (CAPS) of 5056 subjects with
a mean age of 50.1 years (range, 19 to 90 years). In this study, IMT of the
common carotid artery, the carotid bifurcation, the internal carotid artery,
and vascular risk factors were obtained at baseline. In follow-up, stroke,
myocardial infarction, and death were determined prospectively. Cox pro-
portional hazard and regression models were used to determine end points
and factors affecting end points in 2436 subjects younger than 50 years of
age and 2620 subjects aged 50 years old or older.
During a mean follow-up of 4.2 years, there were 107 strokes, 228
myocardial infarctions, and 50 deaths. IMT at all carotid segments was
highly predictive of all end points. Hazard rate ratios (HRRs) per one
standard deviation of common carotid artery IMT increase were 1.43 (95%
confidence interval [CI] 1.35 to 1.51) for myocardial infarction, 1.47 (95%
CI, 1.35 to 1.60) for stroke, and 1.45 (95% CI, 1.38 to 1.52) for the
combination of myocardial infarction, stroke, or death (P  .0001 for all).
Adjusting for sex, age, and vascular risk factors, the predictive values for
bifurcation, IMT, and common carotid artery IMT remained significant for
myocardial infarction and the combined end point. The HRRs for the
combined end point were higher in younger than in older subjects: the
HRRs per 0.1 mm common carotid artery IMT were 1.34 (95% CI, 1.16 to
1.55) versus 1.10 (95% CI, 1.05 to 1.15; P  0.011) for age-IMT interac-
tion.
Comment: Carotid IMT is clearly a marker of vascular risk. This study
suggests that the risk associated with increases in IMTmay actually be higher
in younger than older individuals. IMTmeasurements provide extraordinar-
ily interesting epidemiologic information. It is, however, time to move
forward and determine whether patients with increased IMT levels can be
targeted for modification of atherosclerotic risk factors and a decrease in late
vascular event rates.
Endovascular radiofrequency obliteration using 90°C for treatment of
great saphenous vein
Dunn CW, Kabnick LS, Merchant RF, et al. Ann Vasc Surg 2006;20:625-9.
Conclusion:The time required to perform radiofrequency obliteration
of the great saphenous vein (GSV) can be reduced using 90°C and increased
catheter pullback rates.
Summary: Slower catheter pullback rates using radiofrequency oblit-
eration are cited by some as a disadvantage of this procedure for obliteration
of the GSV when compared with laser obliteration of the GSV. Radiofre-
quency obliteration of the GSV, known as the Closure (VNUS Medical
Technologies, San Jose, Calif) procedure, is performed at a recommended
temperature of 85°C for the catheter, with pullback rates of 2 to 3 cm/min
to achieve durable occlusion of the GSV. Typical time to obliterate the GSV
once the catheter is inserted is therefore 15 to 18 minutes. In this study, the
authors evaluated the use of a 90°C catheter temperature and 5 to 6 cm/min
pullback rates with respect to the ability of this protocol to achieve durable
occlusion of the GSV. Tumescent infiltration along the course of the GSV
was used in all cases. The Closure procedure was performed in 85 limbs of 68
patients using the new protocol. All had ultrasound documented saphe-
nofemoral valve reflux. Patients were evaluated for occlusion of treated vein
segments at 3 days and 6 months postoperatively and for complications at 3
days and 6 months postoperatively.
At 3 days, 96% of GSVs (80/83) were occluded and 90% (66/73) were
occluded at 6 months. There was no evidence of deep venous thrombosis or
skin burns at 3 days or 6 months. The increased pullback rates shortened
catheter total pullback time from 15 to 18 minutes to 8 minutes.
Comment: Faster treatment times have led some clinicians to prefer
laser obliteration of the GSV over radiofrequency obliteration. However, it
does appear now that both techniques can be performed with similar
catheter pullback times. Given the “door-to-door” total time required for a
catheter-based obliteration of the GSV, it does, however, seem a bit silly to
be concerned over 7 or 8 minutes.
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and
GP IIIa and response to aspirin and clopidogrel
Lev EI, Patel RT, Guthikonda S, et al. Thromb Res 2007;119:355-60.
Conclusion: The variable response to antiplatelet drugs appears to be
multifactorial and not related to single gene mutations.
Summary: Individual patients have a variable response to aspirin and
clopidogrel. Several platelet receptor polymorphisms result in increased
platelet aggregation. The purpose of this article was to determine whether
the altered response to aspirin or clopidogrel is due to these platelet
polymorphisms.
The study included 120 patients undergoing percutaneous coronary
intervention. All received aspirin for more than 1 week and none received
clopidogrel. Blood samples were obtained at baseline, and 20 to 24 hours
after a 300-mg clopidogrel dose. The definition of aspirin insensitivity was
5M adenosine diphosphate (ADP)–induced aggregation of 70% and 0.5
mg/mL arachidonic acid-induced aggregation of 20%. The definition of
clopidogrel insensitivity was defined as a baseline minus post-treatment
aggregation change of 10% in response to 5 and 20 M ADP. PLA polymor-
phism of glycoprotein IIIa, T744C polymorphism of P2Y12 gene, and the
1622AG polymorphism of the P2Y1 gene were genotyped by polymerase
chain reaction.
The authors found no differences in polymorphism frequencies be-
tween drug-sensitive and drug-insensitive patients. When patients were
grouped according to genotype, there were no significant differences in
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response to aspirin as assessed by arachidonic acid-induced aggregation or in
response to clopidogrel as assessed by ADP-induced aggregation or activa-
tion markers. There was a trend observed for lower reduction in PAC-1
binding after administration of clopidogrel in PLA2 carriers (P  .065).
Comment: This study reached somewhat different conclusions than
others on this subject in that it did not find an association between polymor-
phism of the PL (A1/A2) gene and aspirin insensitivity. Others have found
such a correlation (Br J Hemotol 2000;110:965-7). The authors studied
slightly different patients and used slightly different assays than previous
studies. This may be part of the explanation for their findings. It is also
possible various drug interactions, platelet turnover, drug absorption, and
individual metabolism also can affect aspirin and clopidogrel sensitivity.
Has evidence changed practice? Appropriateness of carotid endarterec-
tomy after the clinical trials
Halm EA, Tuhrim S, Wang JJ, et al. Neurology 2007;68:187-94.
Conclusion: The randomized trials of carotid endarterectomy (CEA)
have resulted in a reduction in the proportion of patients undergoing CEA
for inappropriate reasons.
Summary: The stimulus for the random trials of CEA was, in part, a
publication from the RANDCorporation indicating a high level of inappro-
priate performance of CEA. In the current report, the authors sought to
assess whether the random trials of CEA changed the level of inappropriate
surgery. This was a patient-based cohort study of all CEAs performed on
elderly patients from January 1988 through June 1999 in New York. Data
were extracted from charts to assess appropriateness of surgery and clinical
indications. A list of 1557 indications for CEA was developed using RAND
appropriateness methods. In addition to indications for surgery, deaths and
strokes within 30 days were determined.
There were 9588 patients in the study. Mean age was 74.6 years. The
level of carotid stenosis was 70% to 99% in 93.6% of patients. Of these, 72.3%
underwent CEA for asymptomatic stenosis. Other indications for operation
were stroke in 9.1% and transient ischemic attack in 18.6%. Based on
pre-established criteria, 87.1% of CEAs were done for appropriate reasons,
4.3% for uncertain reasons, and 8.6% for inappropriate reasons. This was
compared with 32% of CEAs performed for inappropriate reasons before the
publication of the random trials of CEA (P .0001). Of the CEAs classified
as inappropriate, the most common reason was high comorbidity in an
asymptomatic patient (62.2%), CEA after a major stroke (14.2%), or CEA
for minimal stenosis (10.5%). When asymptomatic patients were operated
on and had high comorbidity, the risk of death or stroke more than doubled
compared with those with low or standard levels of comorbidities (7.13% vs
2.69%, P  .0001).
Comment: The article indicates that surgeons pay attention to good
scientific evidence and incorporate that evidence into their practice. Our
European colleagues, however, must be amazed at the high proportion of
CEAs performed for asymptomatic stenosis in the United States. Given that
there is a low therapeutic margin for carotid intervention for asymptomatic
stenosis, it is difficult to understand why a high-risk asymptomatic patient
should undergo any type of carotid intervention.
Long-term low-molecular-weight heparin verses usual care in proxi-
mal-vein thrombosis patients with cancer
Hull RD, Pineo GF, Brant RF and the LITE Trial Investigators. Am J Med
2006;119:1062-72.
Conclusion: In patients with cancer and proximal venous thrombosis,
low-molecular-weight heparin (LMWH) prevents recurrent venous throm-
boembolism (VTE) more effectively than warfarin therapy.
Summary: Recurrent VTE is more common in patients with cancer
than noncancer patients. There also appears to be a reduction in cancer
mortality in patients with VTE and cancer when treated with LMWH. In
addition, it appears vitamin K antagonists are associated with higher rates of
bleeding in secondary prevention of VTE in patients with cancer compared
with those patients treated with long-term LMWH. Other studies have also
suggested LMWH reduces VTE recurrence in patients with cancer (N Engl
J Med 2003;349:146-53). This trial evaluated LMWH vs vitamin K antag-
onist therapy for prevention of recurrent of VTE in cancer patients with
proximal venous thrombosis.
Patients in this multicenter, randomized, open-label clinical trial had
acute symptomatic proximal vein thrombosis and cancer. Patients were
randomized to long-term tinzaparin subcutaneously once daily vs usual care
long-term vitamin K antagonist therapy. Treatment was for 3 months.
Outcomes were assessed at 3 and 12 months. Recurrent VTE was diagnosed
by ultrasound imaging when there was a noncompressible venous segment
that previously was compressible. Recurrent VTE was diagnosed by venog-
raphy when there was a luminal filling defect not present on a baseline
venogram. Pulmonary embolism was confirmed by high probability ventila-
tion perfusion lung scans, pulmonary computed tomography scanning,
pulmonary angiography, or findings of pulmonary embolism at autopsy.
Patients were also assessed for both major and minor bleeding.
There were 200 patients randomized: 100 received tinzaparin and 100
received the usual vitamin K antagonist care. At 12 months, there was a 16%
incidence of recurrent VTE in the patients treated with vitamin K antago-
nists. There was a 7% recurrence of VTE in patients treated with LMWH (P
 .044; risk ratio  0.44; absolute difference –9.0; 95% confidence interval
[CI] –21.7 to –0.7). Bleeding was largely minor and occurred in 24 patients
receiving vitamin K antagonists and 27 patients receiving tinzaparin therapy
(absolute difference, –3.0; 95% CI, –9.l to 15.1). In those patients who had
no additional risk factors for bleeding, there were no major bleeding
episodes in the tinzaparin-treated patients (0/51) and only one incidence of
major bleeding in the patients receiving vitamin K antagonists (1/48).
There was a 47% mortality rate in each group at 1 year, with most of the
deaths secondary to cancer.
Comment: This article failed to confirm a cancer-related death survival
benefit in patients with cancer and proximal venous thrombosis treated with
LMWH.However, the patients in this study had advanced cancer, and many
had advanced metastatic disease. Previous studies suggested survival benefit
occurs only in those without metastatic disease (J Clin Oncol 2005;23:2123-
9). Nevertheless, patients with advanced cancer and proximal venous throm-
bosis may have improved quality of life through LMWH. Certainly, the lack
of need for laboratory monitoring, minimal bleeding risk, and decreased
recurrence of VTE would logically appear to improve quality of life. How-
ever, these patients are deteriorating from multiple reasons that may also
impair quality of life, and unfortunately, the authors did not include quality-
of-life assessment as part of their protocol.
Subintimal angioplasty of supra- and infrageniculate arteries
Aarts F, Blankensteijn JD, van der Vliet JA, et al. Ann Vasc Surg 2006;20:
620-4.
Conclusion: In this study, subintimal angioplasty provided only mod-
est technical and clinical success.
Summary: This was a single-center retrospective review of subintimal
angioplasty performed for chronic limb ischemia. The procedures were
performed betweenOctober 2002 andDecember 2004. Data were analyzed
for patient demographics, technical and clinical success, limb salvage, and
comorbidities.
There were 39 subintimal angioplasties performed in 37 patients.
Median age was 73 years, and approximately two thirds were men and one
third were women. Median follow-up was 9 months. Mortality at 30 days
was 8%. All-cause mortality at 24 months was 33%. Subintimal angioplasty
was limited to the superficial femoral artery in 23 cases (59%). In nine limbs
(23%), both the superficial femoral and popliteal/crural vessels were treated,
with the popliteal artery alone treated in three limbs, and crural arteries alone
treated in four limbs.
Initial technical success was 67%. Clinical success was 49%. Complica-
tions occurred in 11 patients (28%). Three complications were major and
included two acute arterial occlusions and one retroperitoneal hematoma.
An additional 24 surgical interventions were performed after the initial
angioplasty procedure, of which 12 were major amputations. Amputation-
free survival was 69% at 12 months (95% confidence interval 52% to 85%).
Comment: This obviously was a difficult group of patients with a high
amputation rate and a poor survival rate. Success rates reported in this study
for subintimal angioplasty are somewhat lower than those reported else-
where. Subintimal angioplasty is a technically demanding procedure. It may
be the authors were still on the learning curve. However, I suspect the results
reported here are what most would achieve applying this procedure to a
similar difficult cohort of patients.
The novel phosphodiesterase inhibitor NM-702 improves
claudication-limited exercise performance in patients with periph-
eral arterial disease
Brass EP, Anthony R, Cobb FR, et al. J Am Coll Cardiol 2006;48:2539-45.
Conclusion: In patients with claudication, use of NM-702 for 24
weeks is associated with improvements of ambulatory-based exercise perfor-
mance and laboratory-based exercise performance.
Summary: The authors tested the ability of NM-702 to improve
symptoms of intermittent claudication and exercise performance. NM-
702 is a phosphodiesterase inhibitor, as well as a thromboxane A2
synthase. This was a placebo-controlled, double-blind, randomized mul-
ticenter trial. Patients received 24 weeks of twice-daily treatment with 4
mg (n  126) or 8 mg of NM-702 (n  130), or placebo (n  130).
Compared with placebo, after 24 weeks of treatment with 8 mg of
NM-702, there was a significant increase in peak walking time with
graded treadmill exercise. In the placebo group, peak walking time
increased by 17.1%  49.0%. In the 4-mg NM-702 group, peak walking
time increased 22.1%  60.1%. In the 8-mg NM-702 group, peak
walking time increased 28.1%  50.5%. At 24 weeks, the 8-mg dose of
NM-702 was associated with significant improvements in treadmill-
walking claudication onset time compared with placebo. NM-702 also
clearly improved the physical component in physical functioning scores
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